Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 16, 2026
Can you apply?
This grant is for early-stage research into novel pain targets within the understudied druggable proteome, funded by the NIH HEAL Initiative. Eligible applicants include research institutions, universities, independent research institutes, and other organizations with research capabilities (501c3 public charities, research centers, academic medical centers, etc.). The grant supports exploratory and developmental research by new or early-career investigators. Research must focus on discovering new drug targets for pain management, with emphasis on proteins and pathways not yet widely studied as pain therapeutics. Applicants must have appropriate IRB/IACUC approvals for research activities. The R03 mechanism does not allow clinical trials; all research must be preclinical, basic science, or translational in nature. Geographic scope is limited to the United States, though institutions with federal funding eligibility may apply.
Not the right fit? Find grants for your organization in 5 questions →
Program description
The purpose of this notice of funding opportunity (NOFO) is to solicit applications for pilot projects to identify new druggable targets for pain within the understudied druggable proteome. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s) listed in this NOFO. This NOFO is intended to jumpstart research on understudied proteins within the context of pain and pain management and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins to identify new druggable targets for pain. This NOFO is part of the NIH Helping to End Addiction Long Term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.
Who can apply
Eligible applicants
How to apply
Application links
Required documents
- SF-424 (R&R) form and project narrative (typically 6-15 pages depending on NOFO specifics)
- Specific Aims section clearly outlining the research goals
- Research Design and Methods
- Preliminary Results/Data demonstrating feasibility
- Budget and budget justification
- Biographical sketches of key personnel
- Letters of support from institutional leadership
- IRB/IACUC approval documentation or protocol if human subjects/animals are involved
- References and citations
- Current and pending support documentation
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.853 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$56,144,651
-
$40,959,789
-
$35,655,349
-
$35,655,116
-
$35,335,145
-
$34,183,297
-
$32,294,153
-
$32,234,840
-
$31,739,294
-
$27,282,286
Top States by Funding
- MA 5 awards $123.9M
- OH 4 awards $112.5M
- CA 4 awards $101.3M
- FL 3 awards $100.3M
- MI 3 awards $85.3M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.853). How funding has trended year over year.
| 2024 | $2,362,835,459 | |
| 2025 | $2,345,500,401 |
FAQ
What types of organizations are eligible to apply?
Research institutions, colleges, universities, academic medical centers, independent research institutes, and other organizations with demonstrated research capabilities. Applicants must be able to obtain federal funding and have institutional support structures in place.
Can I conduct clinical trials under this grant?
No, clinical trials are explicitly not allowed under the R03 mechanism. All research must be preclinical, basic science, or translational research focused on target discovery.
What should my research project focus on?
Your project should focus on discovering new pain targets within the understudied druggable proteome—essentially identifying novel proteins or biological pathways that could become new pain medications but haven't been extensively studied in this context.
How competitive is this funding mechanism?
R03 grants are designed to support exploratory research with higher success rates than R01 grants, though competition remains significant. Projects with strong preliminary data and clear scientific rationale perform well.
What is the typical funding range?
R03 awards typically range from $150,000 to $300,000 total costs over 2 years, though budget limits may vary. Consult the current NOFO for exact funding parameters.
💡 Tips for applicants
- Emphasize the novelty of your pain targets and why they have been understudied; NIH wants to fund research that fills gaps in the current drug development pipeline.
- Provide strong preliminary data or published evidence that your targets are druggable and relevant to pain biology, even if limited in scope.
- Clearly articulate the significance: explain how discovering new pain targets could benefit pain management and potentially reduce opioid dependency.
- Design a realistic, well-scoped project for the R03 budget and timeline; overly ambitious proposals that would require R01-level funding are less competitive.
- Address potential reviewers' concerns about feasibility early by demonstrating access to necessary resources, equipment, and technical expertise within your institution.
⚠️ Common mistakes
Applications often fail because they lack sufficient preliminary data to support the feasibility of the proposed target discovery research, or they propose work that is too clinically focused rather than basic/translational science. Another common issue is poor justification for why the chosen targets are truly understudied or underexplored in the pain field, failing to distinguish the work from existing literature.
Similar grants
- OPEN HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) — National Institutes of Health
- OPEN HEAL Initiative: Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins and the Nature of (PRECISION) Human Pain Network — National Institutes of Health
- OPEN HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional) — National Institutes of Health
- OPEN Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) — National Institutes of Health